Gaudium IVF and Women Health Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Gaudium IVF and Women Health (NSE: GAUDIUM) is scheduled to declare its Q4 FY26 results on May 15, 2026, when the board of directors will approve the audited financial statements for the January–March 2026 quarter and the full year FY2025–26. The stock trades at Rs 185 as of April 2026 — down -37% from its 52-week high of Rs 298 — making this a closely watched quarter for investors assessing whether the correction represents opportunity or ongoing fundamental pressure.

This Q4 FY26 results preview for Gaudium IVF and Women Health covers the confirmed results date, analyst consensus estimates, five key performance factors, five risks to monitor, analyst ratings, and the complete share price outlook. Q4 FY26 is particularly significant as it delivers the full-year FY26 results alongside the first management commentary on FY27 business outlook.

Get free investment predictions from SEBI-registered analysts on Univest.

Gaudium IVF and Women Health Q4 Results 2026 Date

The Gaudium IVF and Women Health Q4 FY26 results date is May 15, 2026. The board of directors meeting will approve the quarter and full-year FY26 financial results, consider a final dividend recommendation for FY26, and provide management guidance for FY27.

Why Q4 FY26 Matters

Q4 (January–March 2026) is the final quarter of FY2025–26 and carries the highest informational weight of any quarterly result. Beyond the Q4 standalone performance, investors receive: the complete FY26 annual revenue, PAT, and margin profile; management’s first formal FY27 revenue and margin guidance; the final dividend recommendation; and qualitative commentary on demand environment and competitive dynamics entering the new fiscal year.

For Gaudium IVF and Women Health specifically, Q4 captures the peak-season dynamics of the Healthcare / IVF / Women Health sector — a quarter where operating leverage typically manifests most visibly if demand conditions are favourable.

Gaudium IVF and Women Health Q4 FY26 Earnings Estimates

Gaudium IVF and Women Health Q4 FY26 analyst consensus estimates — Revenue, PAT, Margin | univest.in

Access premium analyst research on Univest.

Based on publicly available analyst consensus data, the following are the Q4 FY26 estimates for Gaudium IVF and Women Health:

Screen Gaudium IVF and Women Health live on the Univest Screener — real-time fundamentals, FII/DII flows, and analyst ratings.

Download the Univest iOS App or Univest Android App for real-time Q4 result alerts.

5 Key Factors Driving Gaudium IVF and Women Health Q4 FY26 Performance

1. India Branded Generic Growth

India pharmaceutical market (IPM) growing at 8–10% annually. Q4 captures year-end prescription momentum and seasonal demand for respiratory and anti-infective products.

2. Export Market Development

Regulated market (US, EU) and emerging market (Africa, CIS) export revenue diversifies beyond the domestic market and typically carries higher margins.

3. New Product Launches

ANDA approvals, new molecule registrations, and brand extensions expand the addressable market within existing therapeutic areas.

4. Field Force Productivity

Medical representative (MR) productivity and coverage quality determine prescription generation. Management commentary on field force efficiency is a key quality indicator.

5. Raw Material API Costs

API (Active Pharmaceutical Ingredient) procurement costs, which depend on Chinese API pricing and domestic manufacturing capacity, determine gross margin trajectory.

5 Risks to Watch in Gaudium IVF and Women Health Q4 FY26

Risk 1: Input Cost Volatility

Raw material and input cost changes can compress margins unexpectedly within a quarter.

Risk 2: Revenue Concentration Risk

Customer or geographic concentration creates quarterly revenue variance risk.

Risk 3: Competitive Pressure

Market competition in the Healthcare / IVF / Women Health sector may intensify, requiring additional price or volume concessions.

Risk 4: Regulatory Environment

Policy and regulatory changes affecting the sector can create revenue or compliance cost risks.

Risk 5: Macroeconomic Sensitivity

Global and domestic macroeconomic conditions — tariffs, interest rates, consumption trends — affect end-market demand.

Gaudium IVF and Women Health Share Price and Analyst Ratings

Gaudium IVF and Women Health share price and analyst ratings — Q4 FY26 preview | univest.in

Conclusion

Gaudium IVF and Women Health Q4 FY26 results on May 15, 2026 will be the most important quarterly event of FY26. At Rs 185 — down -37% from its 52-week high of Rs 298 — the stock enters results season having already priced in significant headwinds. Revenue above Rs 185 Cr with EBITDA 16% would constitute a beat relative to current analyst consensus. Management’s FY27 guidance on 18% IVF cycles YoY trajectory will be the primary re-rating catalyst.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All financial data and analyst estimates are sourced from publicly available information. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making investment decisions.

For more Q4 FY26 results previews, visit Univest Blogs.

Frequently Asked Questions

Q: When is Gaudium IVF and Women Health Q4 results 2026 date?

Gaudium IVF and Women Health Q4 FY26 results date is May 15, 2026. The board will approve the quarter and full-year FY26 financial results, consider a final dividend, and provide FY27 guidance.

Q: What is Gaudium IVF and Women Health Q4 FY26 revenue estimate?

Analyst consensus estimate for Gaudium IVF and Women Health Q4 FY26 revenue is Rs 185 Cr. Q3 FY26 actual revenue was Rs 161 Cr. Actual Q4 results may differ based on operating conditions and management execution.

Q: What is Gaudium IVF and Women Health Q4 FY26 PAT estimate?

Analyst consensus estimate for Gaudium IVF and Women Health Q4 FY26 net profit (PAT) is Rs 14 Cr. Q3 FY26 actual PAT was Rs 12 Cr. Estimates are indicative and subject to quarterly variance.

Q: Will Gaudium IVF and Women Health declare a dividend in Q4 FY26?

Gaudium IVF and Women Health is expected to declare Rs 0 for FY26, subject to board approval at the May 15, 2026 meeting and subsequent shareholder approval at the AGM. Verify actual dividend announcement before making any investment decision.

Q: What is Gaudium IVF and Women Health current share price?

Gaudium IVF and Women Health is trading at Rs 185 as of April 2026 — down -37% from its 52-week high of Rs 298. The 52-week low is Rs 155. Track the live price on the Univest Screener.

Q: What were Gaudium IVF and Women Health Q3 FY26 results?

In Q3 FY26, Gaudium IVF and Women Health reported revenue of Rs 161 Cr and net profit (PAT) of Rs 12 Cr. Q4 FY26 results on May 15, 2026 will provide the full-year FY26 comparison.

Q: When do TCS and Infosys announce Q4 results 2026?

TCS declared Q4 FY26 results on April 9, 2026. Infosys is scheduled for April 23, 2026. Both are covered in detail at univest.in/blogs. Check the earnings calendar table above for other key result dates.

Q: Is Gaudium IVF and Women Health a good investment ahead of Q4 results?

This article does not constitute investment advice. Gaudium IVF and Women Health at Rs 185 trades -37% below its 52-week high of Rs 298. Analyst consensus estimates suggest Q4 FY26 revenue of Rs 185 Cr and PAT of Rs 14 Cr. Review the factors, risks, and analyst ratings above. Consult a SEBI-registered financial advisor before making any investment decision.

Recent Article

Balkrishna Industries Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balkrishna Paper Mills Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

BALAXI PHARMACEUTICALS Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Telefilms Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook

Balaji Amines Q4 Results 2026: Date, Revenue, PAT & Analyst Outlook